Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
